Results of randomized trials comparing autologous stem cell transplantation (ASCT) with chemotherapy.
| . | Study . | EFS/PFS . | OS . | P . | Reference . |
|---|---|---|---|---|---|
| EFS indicates event-free survival; PFS, progression-free survival; OS, overall survival; SDT, standard-dose therapy; S indicates significant P-value; NS, non-significant P-value; NR, not reached | |||||
| SDT vs ASCT | |||||
| IFM | Attal M et al. N Engl J Med. 1996;335:91–97 | ||||
| SDT | 18 m (10% 5 y) | 37 m (12% 5 y) | S | ||
| HDT | 27 m (28% 5 y) | NR (52% 5 y) | |||
| MRC | Child JA et al. N Engl J Med. 2003;348:1875–1883 | ||||
| SDT | 19 m | 42 m | S | ||
| HDT | 31 m | 54 m | |||
| SWOG | Barlogie B et al. J Clin Oncol. 2006;24:929–936 | ||||
| SDT | 14% 7 y | 39% 7 y | NS | ||
| HDT | 17% 7 y | 38% 7 y | |||
| PETHEMA | Blade J et al. Blood. 2005;106:3755–3759 | ||||
| SDT | 33 m | 66 m | NS | ||
| HDT | 42 m | 61 m | |||
| MAGG | Fermand JP et al. J Clin Oncol. 2005;23:9227–9233 | ||||
| SDT | 19 m | 47 m | NS | ||
| HDT | 25 m | 47 m | |||
| Single vs Double ASCT | |||||
| IFM | NS | Attal M. N Engl J Med. 2003;349:2495–2502 | |||
| Single | 25 m (10% 7 y) | 48 m (21% 7 y) | |||
| Double | 30 m (20% 7 y) | 58 m (42% 7 y) | |||
| GIMEMA | Cavo M. J Clin Oncol. 2007;25:2434–2441 | ||||
| Single | 23 m | 46 m | NS | ||
| Double | 35 m | 43 m | |||
| . | Study . | EFS/PFS . | OS . | P . | Reference . |
|---|---|---|---|---|---|
| EFS indicates event-free survival; PFS, progression-free survival; OS, overall survival; SDT, standard-dose therapy; S indicates significant P-value; NS, non-significant P-value; NR, not reached | |||||
| SDT vs ASCT | |||||
| IFM | Attal M et al. N Engl J Med. 1996;335:91–97 | ||||
| SDT | 18 m (10% 5 y) | 37 m (12% 5 y) | S | ||
| HDT | 27 m (28% 5 y) | NR (52% 5 y) | |||
| MRC | Child JA et al. N Engl J Med. 2003;348:1875–1883 | ||||
| SDT | 19 m | 42 m | S | ||
| HDT | 31 m | 54 m | |||
| SWOG | Barlogie B et al. J Clin Oncol. 2006;24:929–936 | ||||
| SDT | 14% 7 y | 39% 7 y | NS | ||
| HDT | 17% 7 y | 38% 7 y | |||
| PETHEMA | Blade J et al. Blood. 2005;106:3755–3759 | ||||
| SDT | 33 m | 66 m | NS | ||
| HDT | 42 m | 61 m | |||
| MAGG | Fermand JP et al. J Clin Oncol. 2005;23:9227–9233 | ||||
| SDT | 19 m | 47 m | NS | ||
| HDT | 25 m | 47 m | |||
| Single vs Double ASCT | |||||
| IFM | NS | Attal M. N Engl J Med. 2003;349:2495–2502 | |||
| Single | 25 m (10% 7 y) | 48 m (21% 7 y) | |||
| Double | 30 m (20% 7 y) | 58 m (42% 7 y) | |||
| GIMEMA | Cavo M. J Clin Oncol. 2007;25:2434–2441 | ||||
| Single | 23 m | 46 m | NS | ||
| Double | 35 m | 43 m | |||